What’s Next for Aptose Biosciences Inchares (NASDAQ:APTO) After Having Less Shares Shorted?

September 16, 2018 - By Robert Reynolds

The stock of Aptose Biosciences Inchares (NASDAQ:APTO) registered a decrease of 0.38% in short interest. APTO’s total short interest was 451,600 shares in September as published by FINRA. Its down 0.38% from 453,300 shares, reported previously. With 150,300 shares average volume, it will take short sellers 3 days to cover their APTO’s short positions.

The stock decreased 1.62% or $0.045 during the last trading session, reaching $2.725. About 167,620 shares traded. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 99.31% since September 16, 2017 and is uptrending. It has outperformed by 83.69% the S&P500.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $94.43 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 2 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aptose Biosciences had 6 analyst reports since March 28, 2018 according to SRatingsIntel. The firm has “Buy” rating given on Monday, April 16 by Roth Capital. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Monday, May 7 by H.C. Wainwright. The stock has “Buy” rating by Roth Capital on Tuesday, June 5. On Wednesday, March 28 the stock rating was maintained by H.C. Wainwright with “Buy”. The rating was maintained by H.C. Wainwright on Monday, April 16 with “Buy”. The company was maintained on Friday, June 15 by H.C. Wainwright.

Another recent and important Aptose Biosciences Inc. (NASDAQ:APTO) news was published by Globenewswire.com which published an article titled: “Aptose to Present at Upcoming Investor Conferences in September 2018” on August 29, 2018.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.